Immuneering (IMRX) Equity Average (2020 - 2026)
Immuneering's Equity Average history spans 7 years, with the latest figure at $212.5 million for Q1 2026.
- On a quarterly basis, Equity Average rose 410.64% to $212.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $212.5 million, a 410.64% increase, with the full-year FY2025 number at $129.9 million, up 96.93% from a year prior.
- Equity Average came in at $212.5 million for Q1 2026, down from $223.2 million in the prior quarter.
- The five-year high for Equity Average was $223.2 million in Q4 2025, with the low at $35.4 million in Q2 2025.
- Historically, Equity Average has averaged $109.4 million across 5 years, with a median of $106.4 million in 2023.
- Biggest five-year swings in Equity Average: soared 688.19% in 2022 and later tumbled 51.2% in 2025.
- Year by year, Equity Average stood at $115.9 million in 2022, then decreased by 16.03% to $97.3 million in 2023, then crashed by 49.07% to $49.6 million in 2024, then soared by 350.48% to $223.2 million in 2025, then dropped by 4.81% to $212.5 million in 2026.
- Business Quant data shows Equity Average for IMRX at $212.5 million in Q1 2026, $223.2 million in Q4 2025, and $128.5 million in Q3 2025.